Zobrazeno 41 - 50
of 122
pro vyhledávání: '"Ben Markman"'
Autor:
Quincy Siu-Chung Chu, Sylvie Rottey, Ben Markman, Takafumi Koyama, Jean-Pascal Machiels, Paul de Souza, Kyaw L. Aung, Jeffrey M. Clarke, Heather E. Vezina, Michael Millward, Armando Santoro, Sandip Pravin Patel, Chunsheng He, Kimberley M. Heinhuis, Michelle Brown, Martijn P. Lolkema, Matteo Duca, Giuseppe Curigliano
Publikováno v:
CLINICAL CANCER RESEARCH
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, no.1, p. 95-105 (2022)
Clinical Cancer Research, 28(1), 95-105. American Association for Cancer Research Inc.
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, no.1, p. 95-105 (2022)
Clinical Cancer Research, 28(1), 95-105. American Association for Cancer Research Inc.
Purpose: To assess the safety and tolerability of BMS-986148, a mesothelin-directed antibody–drug conjugate (ADC) ± nivolumab, in patients with selected tumors. Patients and Methods: In an international phase I/IIa study [NCT02341625 (CA008-002)],
Autor:
Ben Markman, Jonathan Cebon, Caroline Lum, Andreas Behren, Clare Senko, Bo Gao, Jodie Palmer, Damien Kee, Oliver Klein, Matteo S. Carlino, Louise Jackett
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Oncoimmunology
article-version (VoR) Version of Record
Oncoimmunology
article-version (VoR) Version of Record
Background: Adrenocortical carcinoma is a rare malignancy, with poor prognosis and limited treatment options for patients with advanced disease. Chemotherapy is the current standard first-line treatment, providing only a modest survival benefit. Ther
Autor:
Sarina A, Piha-Paul, Kyaw Z, Thein, Paul, De Souza, Richard, Kefford, Tara, Gangadhar, Christopher, Smith, Shelly, Schuster, William C, Zamboni, Claire E, Dees, Ben, Markman
Publikováno v:
Investigational new drugs. 39(4)
Background This was a phase I/IIa study to investigate the tolerability, efficacy and pharmacokinetics (PK)/ pharmacodynamics (PD) of CRLX301, CDP-based nanoparticle formulation of docetaxel. Methods The study was conducted in two parts. In part 1, d
Autor:
Oliver Klein, Ben Markman, Damien Kee, Jonathan Cebon, Matteo S. Carlino, Andreas Behren, Craig Underhill, D. Power, Jodie Palmer
Publikováno v:
Cancer Cell. 39:592-593
Autor:
Louise Jackett, Andreas Behren, Niall C. Tebbutt, Matteo S. Carlino, Jodie Palmer, Michael Michael, Jonathan Cebon, Caroline Lum, Adnan Nagrial, Craig Underhill, Ben Markman, Damien Kee, Oliver Klein
Publikováno v:
JAMA Oncol
Importance Biliary tract cancers represent a rare group of malignant conditions with very limited treatment options. Patients with advanced disease have a poor outcome with current therapies. Objective To evaluate the efficacy and safety of combinati
Autor:
Liang Liang, Kyung Hun Lee, Yee Chao, Jong Seok Lee, Chia Jui Yen, Yun Zhang, Chia-Chi Lin, Chang Hsien Lu, Michael B. Jameson, Andrew G. Hill, Ben Markman, Shahneen Sandhu, Virginia E. Paton, Michael Friedlander, John Wu, Yoon-Koo Kang, Kun Ming Rau, Ming Mo Hou, Bhumsuk Keam, Chi Yuan Wu, Jayesh Desai, Michael Millward, Lisa G. Horvath, Sanjeev Deva, Paula Barlow
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundThe programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigational
Autor:
Evangeline Samuel, Mark Shackleton, Sagun Parakh, Paul Mitchell, Gabrielle Lie, Mark Voskoboynik, Adithya Balasubramanian, Thomas John, Ben Markman, Peter Briggs, Andrew Haydon, Maggie Moore, Alison Hiong, Yeojeong So
Publikováno v:
Clinical lung cancer. 22(3)
Background The impact of radiotherapy (RT) on the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in patients with metastatic non–small-cell lung cancer (NSCLC) is unclear. Materials and Methods We identified patients with metastatic N
Autor:
John Wu, Andrew G. Hill, Michael Millward, Catherine Barrow, Christopher Jackson, Michael P. Brown, William F. Patterson, Wendy Huang, Zhiyu Tang, Victoria Atkinson, Gary Richardson, Hui K Gan, Ben Tran, Yunxin Chen, Dewan Zeng, Lisa G. Horvath, Lusong Luo, Andrew Haydon, Michael B. Jameson, Lai Wang, Ben Markman, Jayesh Desai, Stephen Begbie, Phillip Parente, Adnan Nagrial, Benjamin Solomon, Michael Friedlander
Publikováno v:
Journal of Clinical Oncology
PURPOSE Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, and efficacy of lifirafenib
Autor:
Leonel Hernandez-Aya, Saby George, Shivaani Kummar, Leisha A. Emens, Andrew Hotson, Joshua Brody, Ben Markman, Dale R. Shepard, Daruka Mahadevan, Jonathan W. Goldman, Matthew D. Hellmann, Brian Munneke, Daniel J. Renouf, Lawrence Fong, Richard A. Miller, Lyudmyla Berim, Jason J. Luke, Mario Sznol, Amy Weise, Stephen Willingham, Ian McCaffery, Rebecca S. Heist, John D. Powderly, Toni K. Choueiri, Long Kwei, Matthew J. Riese, Po Y. Ho, Ginna G. Laport, Brian I. Rini, Jessica Hsieh, Philip Bonomi, Rachel Anne Goodwin, Brett G.M. Hughes
Publikováno v:
Cancer discovery, vol 10, iss 1
Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinical trial wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75de947792f88bb354890c23b61fe49
https://escholarship.org/uc/item/3vq7n8qs
https://escholarship.org/uc/item/3vq7n8qs
Publikováno v:
Critical reviews in oncology/hematology. 152
Background Chemotherapy-induced nausea and vomiting (CINV) is the most common non-haematological toxicity of chemotherapy. Methods A systematic review and meta-analysis comparing short course (1–2 days) with long course (3+ days) dexamethasone in p